



Revolutionize Your PD-1 Research with RMP1-14-LALAPG



The Next Generation of RMP1-14: Enhanced Efficacy, Lower Doses, Clearer Results

Tumor Growth Inhibition: Tumor Volume Over Time



Unleash the Power of LALAPG Technology

ICH1182LALAPG, our murinised LALAPG version of the gold-standard RMP1-14 antibody, demonstrates superior tumor growth inhibition compared to the traditional RMP1-14 (BE0146).

Key Advantages:


1. Enhanced Tumor Killing Effect: Statistically significant improvement in tumor growth inhibition ($p < 0.05$ on days 3, 5, and 14)
2. Potential for Lower Dosing: Achieve better results with less antibody
3. Improved Experimental Clarity: Set a new baseline for anti-PD-1 efficacy in your studies



Revolutionize Your PD-1 Research with RMP1-14-LALAPG



Body Weight Change Over Time



Maintain Research Integrity with Comparable Safety Profile

ICH1182LALAPG shows a similar impact on body weight as traditional RMP1-14, ensuring continuity in your experimental protocols.

Why Switch to ICH1182LALAPG?

1. Optimize Your Research: Achieve more pronounced effects with the same or lower doses
2. Enhance Sensitivity: Better differentiate the impact of your novel therapeutics from baseline anti-PD-1 effects
3. Streamline Experiments: Potential for shorter study durations or reduced animal numbers
4. Stay Cutting-Edge: Align your research with the latest advancements in antibody engineering



Revolutionize Your PD-1 Research with RMP1-14-LALAPG



Elevate Your Immuno-Oncology Studies

By incorporating ICH1182LALAPG into your research:

- Gain a clearer understanding of your experimental treatments' efficacy
- Potentially reduce time and resources needed for conclusive results
- Set a new gold standard for anti-PD-1 controls in your lab

Expert Opinion

"ICH1182LALAPG represents a significant leap forward in anti-PD-1 antibodies for preclinical research. Its enhanced tumor growth inhibition properties offer researchers a more powerful tool to evaluate novel cancer therapies." - Dr. Elaine Zhang, Lead Researcher

Ready to Upgrade Your Research?

Contact us today to learn how ICH1182LALAPG can transform your immuno-oncology studies.

More information:

stratech.co.uk/ichorbio/revolutionize-your-pd-1-research-with-rmp1-14-lalapg/



stratech.co.uk/ichorbio



info@stratech.co.uk
+44 (0) 1638 782600

 @stratech_uk
 @stratech-scientific-ltd
 @stratech.scientific

www.stratech.co.uk



we plant a tree
for every
order placed



we offer a full
product
guarantee



free delivery for
all UK
Universities



outstanding
technical
support